During a live event, Thomas LeBlanc, MD, MA, discussed dose escalation of luspatercept in myelodysplastic syndromes and ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Marwan G. Fakih, MD, discusses the top takeaways from using combination treatment in metastatic colorectal cancer.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Antonio Jimenez Jimenez, MD, discusses the ACCESS study using HLA-mismatched unrelated donors for peripheral blood and bone ...

The FDA approves a rapid test for identifying patients with NSCLC eligible for sunvozertinib, enhancing timely, precision ...

Panelists discuss how the future treatment landscape for myeloproliferative neoplasms is evolving with many promising ...

Arturo Loaiza-Bonilla, MD, MSEd, systemwide chief of hematology and oncology at St. Lukes University Health Network and ...

Luspatercept-aamt shows significant survival benefits and transfusion independence in lower-risk MDS, reshaping treatment ...

Panelists discuss how rusfertide, a hepcidin mimetic peptide, shows promise in polycythemia vera by reducing phlebotomy ...

A panelist emphasizes that treatment decisions for anemia in low-risk myelodysplastic syndrome should be guided by symptoms ...

A panelist explains how the distinct mechanisms of erythropoiesis-stimulating agents (ESAs), luspatercept, and imetelstat ...